Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Lymphoma 201Leukemia 159Leukemia, Myeloid, Acute 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 112Multiple Myeloma 111Lymphoma, Large B-Cell, Diffuse 108Lymphoma, Follicular 93Hodgkin Disease 92Burkitt Lymphoma 91Myelodysplastic Syndromes 87Lymphoma, Mantle-Cell 87Breast Neoplasms 85Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Large-Cell, Immunoblastic 73Lymphoma, B-Cell, Marginal Zone 59Sarcoma 54Neoplasms, Plasma Cell 50Neuroblastoma 49Central Nervous System Neoplasms 46Leukemia, Myeloid, Chronic-Phase 43Recurrence 40Ovarian Neoplasms 39Leukemia, Myeloid, Accelerated Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Dendritic Cell Sarcoma, Interdigitating 38Blast Crisis 34Leukemia, Myelomonocytic, Chronic 32Neutropenia 29

Interventions

AP 1903 reagent 3ON 01910 2Biopsy 2thymoglobulin 1fludarabine phosphate 1fludarabine 1epacadostat 1decitabine and cedazuridine drug combination 1cedazuridine 1angiotensin I (1-7) 1Vitamin B 12 1Therapeutics 1Specimen Handling 1Sertraline 1Pluvicto 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Interleukin-8 1Immunotherapy, Adoptive 1IDO-1 inhibitor LY3381916 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1Genetic Counseling 1Folic Acid 1Filgrastim 1Exercise 1Emapalumab 1Decitabine 1DNA 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytopenia × Filgrastim × Clear all
NCT02143830 2025-11-12

RAFA

Children's Hospital Medical Center, Cincinnati

Phase 2 Recruiting
70 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Fanconi Anemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡